T2-weighted MRI signal predicts hormone and tumor responses to somatostatin analogs in acromegaly

1. View larger version:

   • In this window
   • In a new window

   • Download as PowerPoint Slide

   Figure 1

   Correlation between the visual assessment of T2-weighted signal intensity and the ROI measurement.
2. View larger version:

   • In this window
   • In a new window

   • Download as PowerPoint Slide

   Figure 2

   Responses of random GH (A), IGF-1% (B) and volume (C) to SSA primary treatment depending on T2-weighted signal intensity.
3. View larger version:

   • In this window
   • In a new window

   • Download as PowerPoint Slide

   Figure 3

   Correlation between quantitative T2-weighted signal intensity of adenomas and their response to SSA in terms of GH (A), IGF-1% (B) and volume (C). GM, grey matter.
4. View larger version:

   • In this window
   • In a new window

   • Download as PowerPoint Slide

   Figure 4

   IGF-1% reduction under treatment depending on T2-weighted signal at diagnosis. The dotted line corresponds to 100% of the ULN.
5. View larger version:

   • In this window
   • In a new window

   • Download as PowerPoint Slide

   Figure 5

   Examples of volume and IGF-1 (% ULN) responses to SSA treatment in GH-secreting pituitary adenomas with different T2-weighted signals.

• © 2016 Society for Endocrinology